← Landscape

🔍 Knowledge Gaps — all (3545 total)

All Oncology Neurodegeneration
TitleStatusVerticalMONDO IDDomainPriority
Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)resolvedneurodegeneration0.98
Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)partially_addressedneurodegeneration0.98
Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)partially_addressedneurodegeneration0.98
What delivery mechanisms can achieve therapeutically relevant CRISPR concentratipartially_addresseddrug-delivery0.95
Senescent cell clearance as neurodegeneration therapyresolvedneurodegeneration0.95
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)partially_addressedneurodegeneration0.95
Does TFEB dysfunction causally drive neurodegeneration or represent compensatorypartially_addressedmolecular-biology0.95
Immune atlas neuroinflammation analysis in neurodegenerationpartially_addressedneuroinflammation0.95
Neuroinflammation and microglial priming in early Alzheimer's Diseasepartially_addressedneurodegeneration0.95
Tau propagation mechanisms and therapeutic interception pointspartially_addressedneurodegeneration0.95
How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegeninvestigatingneurodegeneration0.95
Circuit-level neural dynamics in neurodegenerationpartially_addressedneuroscience0.95
CRISPR-based therapeutic approaches for neurodegenerative diseasespartially_addressedneurodegeneration0.93
Methodology challenge: notebook 'Mitochondrial transfer between neurons and gliaresolvedneurodegeneration0.92
Gene expression changes in aging mouse brain predicting neurodegenerative vulnerresolvedneurodegeneration0.92
Gene expression changes in aging mouse brain predicting neurodegenerative vulnerresolvedneurodegeneration0.92
Methodology challenge: notebook 'Blood-brain barrier transport mechanisms for anresolvedneurodegeneration0.92
Gene expression changes in aging mouse brain predicting neurodegenerative vulnerresolvedneurodegeneration0.92
Gene expression changes in aging mouse brain predicting neurodegenerative vulnerpartially_addressedneurodegeneration0.92
Gene expression changes in aging mouse brain predicting neurodegenerative vulnerresolvedneurodegeneration0.92
Methodology challenge: dataset 'Allen Brain SEA-AD Single Cell Dataset' — evaluaresolvedneurodegeneration0.92
Methodology challenge: dataset 'Allen Brain SEA-AD MTG 10x snRNA-seq' — evaluateresolvedneurodegeneration0.92
Are autophagy-lysosome defects primary drivers or downstream consequences in spopartially_addressedneurodegeneration0.92
Extracellular vesicle biomarkers for early AD detectionpartially_addressedneurodegeneration0.92
Methodology challenge: notebook 'Astrocyte reactivity subtypes in neurodegeneratresolvedneurodegeneration0.92
TREM2 agonism vs antagonism in DAM microgliaresolvedneurodegeneration0.92
Methodology challenge: dataset 'SEA-AD Differential Expression: AD vs Control (Mresolvedneurodegeneration0.92
What evidence supports Cdk5 activation as THE primary cause of AD versus other epartially_addressedneurodegeneration0.91
Blood-brain barrier transport mechanisms for antibody therapeuticspartially_addressedneurodegeneration0.91
APOE4 structural biology and therapeutic targeting strategiespartially_addressedneurodegeneration0.91
Does TFEB dysfunction cause neurodegeneration or represent a compensatory responpartially_addressedneurodegeneration0.9
What are the specific design principles for small molecules that can selectivelypartially_addressedmedicinal-chemistry0.9
Do different priming stimuli create distinct chromatin landscapes or converge onpartially_addressedepigenetics0.9
What are the optimal timing windows for TREM2 inhibition vs activation in Alzheipartially_addressedneurodegeneration0.9
What validated biomarkers can determine optimal TFEB activity windows during dispartially_addressedneurodegeneration0.9
Which cell-type vulnerability signatures from SEA-AD single-cell data represent partially_addressedsystems-biology0.9
Do SPM receptors undergo desensitization with chronic agonist treatment, preventpartially_addressedpharmacology0.9
Do tau aggregates represent protective responses or primary pathogenic drivers ipartially_addressedneurodegeneration0.9
Do P2RX7 antagonists selectively block pathogenic exosomes while preserving benepartially_addressedneurodegeneration0.9
What is the therapeutic window between insufficient and toxic levels of TDP-43 apartially_addressedneurodegeneration0.9
Is ferroptosis the primary driver of motor neuron death in ALS or an epiphenomenpartially_addressedneurodegeneration0.9
Which specific cell types show greatest vulnerability in AD based on SEA-AD tranpartially_addressedneurodegeneration0.9
Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidiresolvedneurodegeneration0.9
testpartially_addressedneurodegeneration0.9
Testopenneurodegeneration0.9
Is myelin loss in AD causal or an adaptive response to neuronal damage?partially_addressedneurodegeneration0.9
Does CXCL10 inhibition compromise CNS immune surveillance during chronic treatmepartially_addressedneuroimmunology0.9
Does APOE4's reduced lipid-binding directly modulate SREBP2-SCAP complex retentipartially_addressedmolecular-biology0.9
What is the relative contribution of connexin-43 gap junctions vs tunneling nanopartially_addressedcell-biology0.9
Which neural cell types exhibit the most pronounced gene expression alterations partially_addressedneurodegeneration0.9
RNA binding protein dysregulation across ALS FTD ADpartially_addressedneurodegeneration0.9
What blood-brain barrier permeability changes serve as early biomarkers for neurinvestigatingneurodegeneration0.9
Blood-brain barrier permeability changes as early biomarkers for neurodegeneratiinvestigatingneurodegeneration0.9
Does structural 'normalization' of APOE4 domain interactions actually improve ampartially_addressedneurodegeneration0.9
Blood-brain barrier permeability changes as early biomarkers for neurodegeneratiinvestigatingneurodegeneration0.9
Do circadian disruptions cause neurodegeneration or result from it?partially_addressedneurodegeneration0.9
Does human glymphatic function show clinically relevant circadian variation likepartially_addressedneurodegeneration0.9
Tau propagation mechanisms and therapeutic interception pointspartially_addressedneurodegeneration0.9
Is disrupted sleep a cause or consequence of neurodegeneration? Analyze the bidipartially_addressedneurodegeneration0.9
What is the evidence for neuronal identity transcription factors as therapeutic investigatingneurodegeneration0.9
How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synuclepartially_addressedneurodegeneration0.9
Does DNAJB6 directly inhibit cross-seeding between tau, α-synuclein, and TDP-43 partially_addressedneurodegeneration0.9
How can circuit-level neurodegeneration mechanisms be identified without completpartially_addressedresearch-methodology0.9
What are the specific molecular mechanisms by which peripheral monocytes cross tpartially_addressedneurodegeneration0.9
Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baspartially_addressedneurodegeneration0.9
Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-synpartially_addressedneurodegeneration0.9
Which specific aging-related gene expression changes in mouse brain predict humapartially_addressedneurodegeneration0.9
Do chronic stress granule inhibition strategies impair normal cellular stress repartially_addressedneurodegeneration0.9
Investigate mechanisms of epigenetic reprogramming in aging neuronspartially_addressedneurodegeneration0.9
Neuroinflammation and microglial priming in early Alzheimer's Diseasepartially_addressedneurodegeneration0.9
Analyze the spectrum of microglial activation states (DAM, homeostatic, inflammapartially_addressedneurodegeneration0.9
How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegeninvestigatingneurodegeneration0.9
Can biased TREM2 agonists selectively activate DAP12-SYK-PI3K without triggeringpartially_addressedmolecular-biology0.9
What are the conserved secondary structures in dilncRNAs that enable selective tpartially_addressedmolecular-biology0.9
Do astrocytes functionally express TRIM46, and can PKCα phosphorylate it to drivpartially_addressedmolecular-biology0.9
Blood-brain barrier permeability changes as early biomarkers for neurodegeneratiinvestigatingneurodegeneration0.9
What is the actual quantitative contribution of FcRn-mediated transcytosis to BBpartially_addressedneuropharmacology0.9
Does C1q function differ based on subcellular localization or binding partner idpartially_addressedneurodegeneration0.9
Do these mechanistic hypotheses explain layer-specific synaptic vulnerability inpartially_addressedneurodegeneration0.9
Do tau-containing vesicles exhibit distinct surface glycosylation patterns compapartially_addressedneurodegeneration0.9
test debatepartially_addressedneurodegeneration0.9
Selective vulnerability of entorhinal cortex layer II neurons in ADpartially_addressedneurodegeneration0.9
What is the high-resolution structure of the APOE4 hinge region and its role in partially_addressedstructural-biology0.9
Can TREM2 receptor switching from agonism to antagonism be achieved safely withopartially_addressedneurodegeneration0.9
Can circadian interventions selectively target microglia without affecting otherpartially_addressedneuropharmacology0.9
Does TFEB activation directly restore mutant GBA enzyme activity or only enhancepartially_addressedmolecular-biology0.9
Do chaperones selectively recognize pathological vs physiological protein conforpartially_addressedprotein-biochemistry0.9
Do stellate neurons express unique α7 nicotinic receptor subtypes that could enapartially_addressedneurodegeneration0.9
APOE4-driven lipid metabolism dysregulation in astrocytes and its role in ADpartially_addressedneuroscience0.9
How can senescent microglia be molecularly distinguished from beneficial activatpartially_addressedneurodegeneration0.9
Investigate mechanisms of epigenetic reprogramming in aging neurons, including Dpartially_addressedneurodegeneration0.9
Does Alectinib truly bind C1q directly with high affinity, or is this an experimpartially_addressedmolecular-biology0.9
What specific gene expression signatures in aging mouse brain predict human AD vpartially_addressedneurodegeneration0.9
Does APOE4 drive tau propagationpartially_addressedneurodegeneration0.9
Are DNA methylation changes in neurodegeneration causal drivers or protective coinvestigatingneurodegeneration0.9
Do migratory animals encode specific spatial locations epigenetically or rely onpartially_addressedbehavioral-neuroscience0.9
Investigate mechanisms of epigenetic reprogramming in aging neuronspartially_addressedneurodegeneration0.9
What are the molecular signatures that distinguish protective vs. harmful microgpartially_addressedneurodegeneration0.9
Neuroinflammation and microglial priming in early ADpartially_addressedneurodegeneration0.9
What is the role of gut microbiome-brain interactions in Parkinson's disease patinvestigatingneurodegeneration0.9
Do oligodendrocytes require DNA repair enhancement or inhibition for neuroprotecpartially_addressedneurodegeneration0.9
What blood-brain barrier permeability changes serve as early biomarkers for neurinvestigatingneurodegeneration0.9
Investigate prion-like spreading of tau pathology through connected brain regionpartially_addressedneurodegeneration0.9
Which tau PTMs are both disease-specific and druggable with selective small molepartially_addressedneurodegeneration0.9
What determines blood-brain barrier penetration kinetics for specialized pro-respartially_addressedneuropharmacology0.9
Do tau strains or regional cellular environments primarily drive PSP vs CBD pathpartially_addressedneurodegeneration0.9
How can CRISPR systems achieve persistent therapeutic effects while avoiding chrpartially_addressedgene-therapy0.9
What are the optimal timing windows for TREM2 agonism vs antagonism across diseapartially_addressedneurodegeneration0.9
Which specific post-translational modifications create druggable epitopes uniquepartially_addressedneurodegeneration0.9
Investigate mechanisms of epigenetic reprogramming in aging neurons, including Dresolvedneurodegeneration0.9
How do gut microbiome-brain interactions contribute to Parkinson Disease pathogeinvestigatingneurodegeneration0.9
Is HCN1 dysfunction causal or protective in EC layer II neurodegeneration?partially_addressedneurodegeneration0.9
How can subcellular compartmentalization defects be measured as biomarkers in lipartially_addressedneuroscience0.9
How can Allen Aging Mouse Brain Atlas data be systematically cross-referenced wipartially_addressedneurodegeneration0.9
Gut-Brain Axis in Parkinson's Disease: Molecular Mechanisms, Neuroinflammation, partially_addressedneurodegeneration0.9
Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects partially_addressedneurodegeneration0.9
What is the optimal ketone dosing threshold to avoid metabolic steal syndrome whpartially_addressedneurometabolism0.9
Do PINK1/PARKIN pathway enhancements rescue excitatory neuron vulnerability or cpartially_addressedneurodegeneration0.9
Do transferred mitochondria from diseased astrocytes carry pathological damage tpartially_addressedneurodegeneration0.9
Does reduced Prevotellaceae abundance cause PD pathology or result from it?partially_addressedneurodegeneration0.9
What determines the temporal transition from protective to pathological stress gpartially_addressedneurodegeneration0.9
What is the therapeutic window between GCS inhibition efficacy and systemic toxipartially_addressedneurodegeneration0.9
Does SYK activation provide neuroprotection or exacerbate neuroinflammation in epartially_addressedneurodegeneration0.9
Can P16INK4A expression reliably distinguish harmful from beneficial senescent mpartially_addressedneurodegeneration0.9
How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegenresolvedneurodegeneration0.9
Can pathological vs physiological C1q tagging be distinguished at the molecular partially_addressedneurodegeneration0.9
Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically repartially_addressedneurodegeneration0.9
What are the specific molecular mechanisms linking ADCY8 to spatial memory consopartially_addressedneuroscience0.9
What distinguishes truly senescent brain cells from merely dysfunctional reactivpartially_addressedcellular-senescence0.9
Mechanistic validation of SEA-AD differential expression hypotheses: Complement partially_addressedneurodegeneration0.9
Can IGFBPL1 therapeutics effectively cross the blood-brain barrier to reach CNS partially_addresseddrug-delivery0.9
What are the molecular determinants that control directional mitochondrial transpartially_addressedcellular-neuroscience0.9
Are age-related DNA methylation changes protective adaptations or pathological dinvestigatingneurodegeneration0.9
What physicochemical properties determine selective protein recruitment vs exclupartially_addressedmolecular-biology0.9
What blood-brain barrier permeability changes serve as early biomarkers for neurinvestigatingneurodegeneration0.9
Which specific post-translational modifications distinguish pathological from phpartially_addressedneurodegeneration0.9
What are the optimal temporal windows for TREM2 inhibition vs activation in Alzhpartially_addressedneurodegeneration0.9
Which specific metabolic pathways in APOE4 microglia are causally linked to dysfpartially_addressedneurodegeneration0.9
Does tau aggregation specifically cause PS externalization in vesicles independepartially_addressedneurodegeneration0.9
Does tau aggregation specifically cause PS externalization in living cells versupartially_addressedneurodegeneration0.9
Do these mechanistic hypotheses from the SEA-AD Atlas bundle explain layer-specipartially_addressedneurodegeneration0.9
What specific gene expression signatures in aging mouse white matter predict humpartially_addressedneurodegeneration0.9
Do PINK1/PARKIN pathway enhancements rescue excitatory neuron vulnerability or epartially_addressedneurodegeneration0.9
What is the therapeutic window between tau propagation inhibition and essential partially_addressedneurodegeneration0.9
What brain concentrations of SCFAs are achieved via oral probiotics and are theypartially_addressedpharmacokinetics0.9
How can functional hyperconnectivity patterns distinguish compensatory mechanismpartially_addressedneurodegeneration0.9
epigenetic reprogramming aging neuronspartially_addressedneurodegeneration0.9
What is the atomic-resolution structure of K280-acetylated tau and how does it tpartially_addressedstructural-biology0.9
What is the optimal BBB opening duration and spatial precision to maximize therapartially_addressedneuropharmacology0.9
Is C1q elevation in AD pathogenic or compensatory for amyloid clearance?partially_addressedneurodegeneration0.9
What is the temporal sequence of sleep disruption versus amyloid-beta accumulatipartially_addressedneurodegeneration0.9
Do tau-specific HSP90 conformational states exist that differ from other client partially_addressedstructural-biology0.9
Investigate mechanisms of epigenetic reprogramming in aging neuronsresolvedneurodegeneration0.9
What are the specific circulating factors in exercise-conditioned plasma that mepartially_addressedneurodegeneration0.89
What are the molecular mechanisms by which GLP-1RAs provide neuroprotective effepartially_addressedneurodegeneration0.89
How does HDAC1/2 deletion specifically enhance microglial amyloid phagocytosis cpartially_addressedneurodegeneration0.89
How does APOE4's beneficial immune function reconcile with its established role partially_addressedneurodegeneration0.89
How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenespartially_addressedneurodegeneration0.89
Why do p300/CBP inhibitors reduce both AD incidence and clinically diagnosed TBIpartially_addressedneurodegeneration0.89
How do P/Q channel deficits paradoxically increase thalamic excitability despitepartially_addressedsynaptic-biology0.89
What molecular mechanisms mediate HDAC9's effects on Aβ deposition and synaptic partially_addressedneurodegeneration0.89
What molecular mechanisms explain how KCNJ2 inhibition mitigates TBI-induced neupartially_addressedneurodegeneration0.89
How does engineered C. butyricum cross the blood-brain barrier to directly bind partially_addressedneurodegeneration0.89
What genetic risk factors predispose individuals to developing CTE following reppartially_addressedneurodegeneration0.89
Does clusterin exacerbate or protect against neuronal death in neurodegenerationpartially_addressedneurodegeneration0.89
What molecular mechanisms link elevated sphingomyelin synthase activity to increpartially_addressedneurodegeneration0.89
Why does PGC-1α overexpression paradoxically increase MPTP toxicity despite enhapartially_addressedneurodegeneration0.89
What molecular mechanisms explain how apoE promotes cerebral amyloid angiopathy partially_addressedneurodegeneration0.89
What molecular mechanisms mediate SPP1-induced microglial phagocytic activation resolvedneuroinflammation0.89
What signals trigger microglia to specifically recognize and phagocytose LC axonpartially_addressedneuroinflammation0.89
What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding tpartially_addressedneurodegeneration0.89
What molecular mechanisms drive neuron-to-glioma synapse formation in high-neurapartially_addressedneuro-oncology0.89
How do the seven novel ALS genes function in animal models to cause neurodegenerpartially_addressedneurodegeneration0.89
How do oligodendrocytes initiate neuroinflammation in PD when microglia are tradpartially_addressedneuroinflammation0.89
Why does autophagy inhibition improve neuronal survival when autophagy is typicapartially_addressedneurodegeneration0.89
What are the physiological functions of BACE1 beyond APP processing that could cpartially_addressedneurodegeneration0.89
What upstream mechanisms trigger p53 activation specifically in response to polypartially_addressedneurodegeneration0.89
What molecular mechanisms determine whether reactive astrocytes adopt neurotoxicpartially_addressedneuroinflammation0.89
What molecular mechanisms drive the transition from acute to persistent neuroinfpartially_addressedneuroinflammation0.89
How does pericyte senescence mechanistically promote glioma cell growth and invapartially_addressedneurodegeneration0.89
Does TRT-induced erythrocytosis actually increase venous thromboembolism risk inpartially_addressedendocrinology0.89
How does PSEN2 mechanistically regulate α-synuclein expression and pathology in partially_addressedneurodegeneration0.89
What molecular mechanisms cause iPLA2β deficiency to specifically damage mitochopartially_addressedneurodegeneration0.89
How do B cells mechanistically orchestrate tolerance to AQP4 and prevent autoimmpartially_addressedneuroinflammation0.89
What molecular mechanisms enable functional recovery and muscle re-innervation apartially_addressedneurodegeneration0.89
Why is TYROBP deficiency neuroprotective when TYROBP is an adapter for multiple partially_addressedneuroinflammation0.89
Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-functionpartially_addressedneurodegeneration0.89
How does PIKFYVE inhibition activate unconventional protein clearance via exocytpartially_addressedneurodegeneration0.89
Why does Metformin fail to delay CJD progression despite improving anti-aging hapartially_addressedneurodegeneration0.89
What mechanisms explain how IDH1/IDH2 mutations with reduced enzymatic activity partially_addressedneurodegeneration0.89
Why does PRKN-mediated mitophagy, typically protective, cause harmful mitochondrpartially_addressedneurodegeneration0.89
Microglia-astrocyte crosstalk amplification loops in neurodegenerationpartially_addressedneurodegeneration0.89
What is the molecular mechanism by which oligodendroglial MCT1 disruption causespartially_addressedneurodegeneration0.89
What molecular mechanisms enable microglia to neutralize OxPC-mediated neurodegepartially_addressedneuroinflammation0.89
What molecular mechanisms underlie the dose-dependent protective effects of the partially_addressedneurodegeneration0.89
What molecular mechanism causes VCP mutations to trigger aberrant HIF-1α activatpartially_addressedneurodegeneration0.89
How do ALS-associated OPTN mutations mechanistically disrupt Rab8a binding and cpartially_addressedneurodegeneration0.89
Why do TAM receptors protect against neuroinvasive viruses despite their known ipartially_addressedneuroinflammation0.89
How does SYNGAP1, a 'synaptic' protein, function in pre-synaptic radial glia celpartially_addressedneurodevelopment0.89
What specific molecular mechanisms link APOE4 to cholesterol dysregulation in olpartially_addressedneurodegeneration0.89